Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1Dermatologic 1

Conditions

Lymphoma 2Uveal Melanoma 1Ovarian Neoplasms 1Neoplasms 1Myelodysplastic Syndromes 1Lymphoma, T-Cell, Cutaneous 1Lymphoma, T-Cell 1Leukemia 1Carcinoma, Ovarian Epithelial 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Cyclophosphamide 32Etoposide 18romidepsin 17fludarabine 17Vincristine 17Doxorubicin 16Rituximab 14Prednisone 14Melphalan 14Gemcitabine 13Brentuximab Vedotin 13Lenalidomide 12Peripheral Blood Stem Cell Transplantation 11Cytarabine 11Whole-Body Irradiation 10Biopsy 1010-propargyl-10-deazaaminopterin 10pembrolizumab 9fludarabine phosphate 9Specimen Handling 9Busulfan 9Mycophenolic Acid 8Granulocyte Colony-Stimulating Factor 8Depsipeptides 8Carmustine 8Bortezomib 8duvelisib 7Vorinostat 7Methotrexate 7Magnetic Resonance Spectroscopy 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Lymphoma, T-Cell × quisinostat × Clear all
NCT01486277 2016-11-03

A Study of the Histone Deacetylase Inhibitor (HDACi) Quisinostat (JNJ-26481585) in Patients With Previously Treated Stage Ib-IVa Cutaneous T-cell Lymphoma

Janssen Research & Development, LLC

Phase 2 Completed
26 enrolled
DermatologicLymphoid

Lymphoma, Lymphoma, T-Cell, Lymphoma, T-Cell, Cutaneous

Data powered by HemOnc (CC BY 4.0) Colophon âš¡